Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique

A Marasso, V Bernardi, R Gai, E Gallo, G M Massaglia, M Onoscuri, S B Cardaci

Abstract

Background — A number of treatments, including Nd-YAG laser therapy, brachytherapy, cryotherapy, electrocautery, and photodynamic therapy, can re-open the obstructed bronchial lumen in patients with inoperable obstructive bronchial tumours. None of these is considered to be a “gold standard”.

Methods — The results of a retrospective study of 98 patients treated by radiofrequency tissue ablation and subsequent cryotherapy between January 1994 and June 1995 are reported. The patients were divided in two groups according to whether they were treated either after (group 1, n = 50) or before (group 2, n = 48) radiotherapy and/or chemotherapy. Bronchoscopic follow-up was performed. The intervention was considered successful if the lumen was opened by >80% and partially successful if it was opened by >50%.

Results — In group 1 treatment was successful in 60%, partially successful in 32%, and unsuccessful in 8%. The median survival time was five months from the time of bronchoscopic surgery. In group 2 treatment was successful in 66%, partially successful in 21.5%, and unsuccessful in 12.5%, with a median survival time of 14 months from the time of bronchoscopic treatment. Forty patients (24 in group 1 and 16 in group 2) received a Dumon stent.

Conclusions — Radiofrequency bronchoscopic surgery with cryotherapy appears to be a useful technique in the treatment of tracheobronchial obstruction.

(Thorax 1998;53:106–109)

Keywords: radiofrequency, cryotherapy, Nd-YAG laser, bronchoscopy, lung cancer.

The aim of endoscopic surgery in patients with malignancies of the tracheobronchial tree is to restore the airway patency in a palliative fashion. Tracheobronchial debulking is known to improve quality of life and may be considered part of first line treatment or even the therapy of choice in patients with medically unresectable early bronchial carcinoma, tumours characterised by a low metastatic potential, or local invasiveness such as carcinoids, adenoid cystic carcinomas and endoluminal benign neoplasms.

Many devices provide effective coagulation and vaporisation, allowing the removal of tumoral masses. The Nd-YAG laser is commonly used in bronchoscopic surgery, and most interventional bronchoscopists consider it as the standard device. Other types of laser (argon dye, krypton ion, helium-cadmium laser) are used in association with chromogens for photodynamic therapy and for early detection of bronchial cancer. In contrast, electrocautery is not widely used in bronchology.

We have used two alternative techniques — radiosurgery and cryotherapy — to treat our patients. Radiosurgery is a new technology which has not previously been used in bronchology. Radiofrequency tissue ablation is a technique for making thermal lesions around the tip of an electrode as a result of tissue coagulation caused by resistive heating. The electrode can be applied directly onto superficial structures surgically, endoscopically, laparoscopically, or via a catheter; the latter technique has become a well established treatment for many symptomatic cardiac arrhythmias. Thermal methods such as the use of radiofrequency induced tissue coagulation were used in early clinical trials for treating osteoid osteomas, hepatic tumours, and lung tissue. When attached to the appropriate generator, radiofrequency energy is emitted from the exposed uninsulated portion of the electrode. This energy translates into ion agitation which is converted into heat and induces cellular death via coagulation necrosis. In theory, radiofrequency can be used to sculpt precisely the volume of necrosis to match the extent of the tumour. Cryosurgery is safe and inexpensive and acts by immediate protein coagulation and cellular rupture by ice crystals and by ischaemic necrosis as a result of microthrombosis in the tumour vessels in the delayed phase.

We report our experience with the combined use of radiosurgery and cryosurgery in operative bronchoscopy for treatment of tracheobronchial tumours. The use of stents can help to maintain the benefits of debulking treatments and these were used when appropriate.

Methods

PATIENTS

The records of 98 patients treated endoscopically for unresectable tracheobronchial malignancy between January 1994 and June 1995 were reviewed retrospectively. In 80 patients the malignancy was a primary carcinoma with endobronchial involvement, 14 were bronchial recurrences of a previously resected non-small cell lung cancer (NSCLC), and four cases were endobronchial metastases...
Radiofrequency resection of bronchial tumours in combination with cryotherapy

were used to resect the endophytic portion of the tumour, operating with the first tool in “cut/coagulation” mode and the second in “coagulation” mode, both in superpulsed emission, power 60–70 W, six impulses per second of 10/100 seconds each. Tumours only partially obstructing the tracheal or the bronchial lumen were resected with the Huzly loop under straightforward telescopic control while tumours that completely obstructed the lumen were mechanically avulsed by coring them out with the tip of the bronchoscope, after a punctiform coagulation was performed with the coagulation probe initially applied on the mass surface and then driven into the mass itself. Tumour pieces were removed by suction, forceps or cryoprobe, by cryoadhesion. The residual tumour infiltrating the bronchial wall was then cryotreated with repeated applications of 1–2′ to obtain a cytotoxic effect deep in the wall (fig 2) and to sensitize the tumour to chemotherapy/radiotherapy in non pre-treated patients (group 1).

Antibiotic coverage was routinely performed after the intervention. One week after cryotherapy bronchial debridement was performed using a rigid bronchoscope and a stent was inserted when indicated using a Herrel-Dumon (Efer, France) bronchoscopic introducer. Stent insertion was restricted to cases where rapid re-stenosis was likely – for example, cases of extrinsic compression. In the other cases we avoided or delayed stent insertion, particularly if we thought that further re-opening of the bronchial lumen could be expected from the chemotherapy/radiotherapy.

The patients were discharged on the same evening whenever possible. Repeat bronchoscopy to assess for re-stenosis was performed at one week and then two monthly thereafter.

Table 1 Summary of patient data

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 50)</th>
<th>Group 2 (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M:F</td>
<td>46:4</td>
<td>44:4</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>66</td>
<td>64</td>
</tr>
<tr>
<td>Age range (years)</td>
<td>45–82</td>
<td>46–74</td>
</tr>
<tr>
<td>Obstruction site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trachea</td>
<td>16% (8)</td>
<td>12.5% (6)</td>
</tr>
<tr>
<td>Right main bronchus</td>
<td>56% (28)</td>
<td>62.5% (30)</td>
</tr>
<tr>
<td>Left main bronchus</td>
<td>32% (16)</td>
<td>21% (10)</td>
</tr>
<tr>
<td>Left lower bronchus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pathology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSCLC</td>
<td>92% (46)</td>
<td>83.3% (40)</td>
</tr>
<tr>
<td>SCLC</td>
<td>8% (4)</td>
<td>8.3% (4)</td>
</tr>
<tr>
<td>Metastases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RS + cryo + CT</td>
<td>87.5% (42)</td>
<td></td>
</tr>
<tr>
<td>RS + cryo + RT</td>
<td>12.5% (6)</td>
<td></td>
</tr>
<tr>
<td>RS + cryo</td>
<td>100% (50)</td>
<td></td>
</tr>
<tr>
<td>Stent</td>
<td>48% (24)</td>
<td>33.3% (16)</td>
</tr>
</tbody>
</table>

NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; RS = radiosurgery; cryo = cryosurgery; RT = radiotherapy; CT = chemotherapy.

TECHNIQUE

Bronchoscopy was performed via a rigid bronchoscope (Storz, Germany or Efer, France) using neuroleptoanalgesia (diazepam 5–10 mg + fentanyl 3–5 μg/kg + propofol 1 mg/kg) to maintain spontaneous ventilation. Blood pressure, electrocardiographic parameters, heart rate, and oxygen saturation were monitored.

The radiofrequency generator used operates at 1750 kHz, maximum power 99 W, in continuous, single, repeated pulse and superpulse emission and with the functions of cut, coagulation, cut/coagulation, and superficial coagulation. A Huzly thermic loop and/or coagulator probe (both Storz, Germany; fig 1) of an extrathoracic malignancy. The patients were divided into two groups according to the time of radiotherapy/chemotherapy; 50 patients were treated after receiving radiotherapy/chemotherapy (group 1) and 48 patients were treated before radiotherapy/chemotherapy (group 2). Details of the patients are given in table 1.

Figure 1 Instruments used for treatment: Huzly diathermy loop (left), coagulator (centre), cryoprobe (right).

Figure 2 Schematic representation of areas treated with radiofrequency ablation surgery and cryosurgery.
by the tumour regrowth and it was replaced with a longer one after further radiofrequency treatment. In another case in group 2 the stent migrated from the right main bronchus toward the tracheal lumen during radiotherapy, probably because of further bronchial reopening, and it was replaced with a larger one.

**Discussion**

The main purpose of interventional bronchoscopy in malignancy is to restore the patency of the airways. This treatment may improve respiratory function, reduce the likelihood of obstructive pneumonia or empyema and, in cases of severe tracheal stenosis, may be life saving. While the treatment may be only symptomatic in patients who have already failed with radiotherapy/chemotherapy, it may allow others to receive this treatment which would otherwise have been contraindicated by severe respiratory failure and/or pleuropulmonary infection. From our experience of bronchoscopic cryosurgery in more than 600 patients treated since 1976 we consider it to be a safe procedure for the treatment of tumours infiltrating the bronchial wall as perforations do not occur even with repeated and prolonged applications.

There are, however, several shortcomings. Survival from the time of bronchoscopic treatment was also evaluated.

**Results**

**GROUP 1**

Debulking was successful in 30 patients (60%), partially successful in 16 (32%), and unsuccessful in four (8%); 24 patients (16 with bronchial cancer and eight with tracheal cancer) received a Dumon stent. Median survival was five months from surgery (range 0–14).

**GROUP 2**

Debulking was successful in 32 patients (66%), partially successful in 10 (21.5%), and unsuccessful in six (12.5%); 16 patients (10 with bronchial cancer and six with tracheal cancer) received a Dumon stent. Radiotherapy was performed in 42 patients (87.5%) within two weeks of cryotherapy at a mean dose of 50 Gy (range 30–60) and six (12.5%) received six cycles of chemotherapy (cyclophosphamide 100 mg/m² + etoposide 80 mg/m²), two for small cell lung cancer (SCLC) and four for NSCLC. Twenty eight died from disease progression with no local recurrence at the radiographic and bronchoscopic follow up. The median survival time was 14 months (range 2–18). At March 1996 20 patients were still alive with no local recurrence, four of whom (two with NSCLC treated with radiotherapy and two with NSCLC treated with chemotherapy) were disease free after >24 months of follow up. The bronchoscopic appearance of a patient before and after treatment with radiotherapy and cryotherapy is shown in fig 3.

No major complications related to the intervention or anaesthesia were observed. Only minor complications occurred in two patients. In one case in group 1 the stent was obstructed by the tumour regrowth and it was replaced with a longer one after further radiofrequency treatment. In another case in group 2 the stent migrated from the right main bronchus toward the tracheal lumen during radiotherapy, probably because of further bronchial reopening, and it was replaced with a larger one.

**MEASUREMENTS**

Bronchoscopic follow up assess for re-stenosis was performed at one week and then two monthly thereafter; the intervention was considered successful when the lumen was re-opened >80% and partially successful if >50%. Survival from the time of bronchoscopic treatment was also evaluated.

**Figure 3** Example of bronchoscopic appearance of patient before (right) and after (left) treatment with radiosurgery and cryotherapy.
Radiofrequency resection of bronchial tumours in combination with cryotherapy

compared with about £40 000 for a Nd-YAG laser). The difference in cost could encourage more widespread use of this technique.

Our retrospective study seems to indicate prolonged survival, but the heterogeneity of the patients with regard to histology, site of obstruction, disease stage, complications, and associated oncological treatment, the retrospective nature of the data, and the lack of a comparative group do not allow a statistical evaluation. It would be of considerable clinical interest to investigate the results of tracheobronchial bronchoscopic treatments in terms of survival in a prospective controlled study.


Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique.
A Marasso, V Bernardi, R Gai, E Gallo, G M Massaglia, M Onoscuri and S B Cardaci

doi: 10.1136/thx.53.2.106

Updated information and services can be found at:
http://thorax.bmj.com/content/53/2/106

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Cardiothoracic surgery (676)
Sports and exercise medicine (92)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/